Pembrolizumab monotherapy for NSCLC: KEYNOTE-024 update

Martin Reck

The Phase III KEYNOTE-024 trial (NCT02142738) compared pembrolizumab monotherapy with standard platinum-based chemotherapy for previously untreated metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, gives an overview of the trial and an update on the progression-free survival results observed in the trial.

Share this video